Fig. 5
The up-regulation of NKCC1 and the down-regulation of KCC2 are responsible for the depolarizing shift of EGABA. (a-d) Graphs showing the impact of NKCC inhibitor bumetanide (BM; 10 μM) and the KCC2 blocker VU0463271 (VU; 5 μM) on the EGABA of the MNCs of the Virgin, Lac1, Lac3 and Dry3 groups of rats. The symbols connected by lines denote data from the same cells. Holm-Sidak all pairwise comparison tests were performed after one-way repeated measures ANOVA (p = 0.001-0.04). Asterisks indicate significant difference from the data obtained before the drug application, while double daggers denote significant difference from the data obtained during the drug application. (e) Bar charts summarizing the hyperpolarizing effects of bumetanide and the depolarizing effects of VU0463271 on the EGABA of the MNCs of different groups of rats. Holm-Sidak all pairwise comparison tests were performed after one-way ANOVA (p < 0.001). Asterisk indicates significant difference of the value of Lac3 group from those of other groups